Alzheimer’s disease remains incurable to this day but in November additional clinical data confirmed the potential for a new druglecanemab, to significantly slow the cognitive decline of patients followed for 18 months.
This drug, developed by the American pharmaceutical group Biogen and the Japanese group Eisai (which is also a partner of Sysmex), also has sometimes severe adverse effects, but it has been widely hailed by the international scientific community as a very promising progress.
More than 55 million people worldwide suffer from dementia, a number that is expected to climb to 130 million by 2050 as life expectancy increases, according to the World Health Organization (WHO). Alzheimer’s disease accounts for approximately 60 to 70% of cases.
Dementia is a major public health problem in Japanthe oldest country in the world (29.1% of its inhabitants were aged 65 and over in 2022, a new record).
